about
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activityEtanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficaciousCD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic diseaseClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early diseaseSustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusAntibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptidesFactors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception CohortTapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationClinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.Sex differences in rheumatoid arthritis: more than meets the eye..Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts.Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS studyLong-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.Ten years with biologics: to whom do data on effectiveness and safety apply?Observational studies: a valuable source for data on the true value of RA therapies.Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsEULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.Diagnostic utility of musculoskeletal ultrasound in patients with suspected arthritis--a probabilistic approachRapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized contDehydroepiandrosterone for the treatment of systemic lupus erythematosus.Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
P50
Q24193435-AEE69110-CF23-47C3-AC27-BD1B6A4A0895Q24795061-C4719EC7-F2D6-4850-952A-0CF213F8BDB5Q24805444-7C9A1CF2-4162-49BB-AA64-BAFFFD972AA3Q26753120-20123AEC-CD27-4840-BBE1-CA6E7F729E5BQ26800154-D692D4EC-2143-4F7E-8DC4-6298D3E73FEAQ28254310-438807C4-6E80-4A0C-81DA-72DC04E02916Q28263011-C7FA530B-C59F-4CC3-B6C7-A74D0B110073Q28608340-68A83D73-DA11-4857-B0CF-31EDB2A52592Q30249836-D1CEEB2A-8EC1-4EB2-88B8-BE4AD167943EQ30608529-3ACD2D08-88EB-4AEA-B3CC-77A10AEE6957Q30645037-96FDEB9F-7325-40F7-9212-53F35EE4BCFDQ30791606-01BAD002-B7BD-4B51-AD2E-3B9CF0AAD80DQ30801601-1165965A-566F-43A2-BD96-0477AAED3891Q30885007-61C2B3E6-F51A-4B14-8A49-B3A4414648CAQ31046441-E2215793-81A2-48FF-94F9-BA2B89AF73B2Q31122937-0851184A-5AA2-4F6B-8E89-C3BE5737DD92Q31145074-62414D6D-A472-45CD-82AD-81206CE5407FQ31151183-83DE85C8-0567-41F8-B825-6F39ABA2B787Q31154802-EBCA1D70-45EC-4229-B0CF-AA6381BEF979Q33284736-755D6389-A780-4995-AFA5-628614F22F20Q33369384-D6C89FAA-4B75-4CB7-B98C-3E94B94D61F7Q33369386-0B7B645A-0E84-4889-8C77-47A047DC7959Q33424033-A6B32881-C99B-46B4-B11C-9B096D6F2085Q33567481-4362E0C3-68AF-49AA-B567-C1FDA5C824D7Q33590773-9F75AA6C-CDCC-4660-9CA4-E21FBF54D961Q33725553-2F700F2B-6AB4-4250-8F22-9937BE7A1657Q33749195-D2339F21-01CB-4D6D-A6D3-B84D9E57B811Q33779130-4A1C9CCD-A548-474B-B1C9-AFDBB8330162Q33899815-AE57FC99-60DF-488E-A71A-7788621CEBEAQ34022672-B1400099-0F3D-4C29-A60A-FAAD29706670Q34095599-72F0733C-901B-4A97-B2CE-3B93CC7A8794Q34110066-E08C8C5D-6370-40DE-8ED8-A57DE2D01FD5Q34132211-945A80FC-CE2F-424C-A217-39F712DA0193Q34292030-808D6D03-CD32-4165-BF98-F561D4199735Q34361748-122C66C5-CC52-4B10-90F1-CBD687C97496Q34402200-084C8A14-B540-453F-B534-85FFF56FAD37Q34413310-96D561E9-EDFE-42F2-BA1D-E02963292F46Q34482021-766BFC6A-3398-4DC8-93B2-C15F051B123EQ34607794-89822D52-50C5-45BE-BD0B-FA3D0E89B801Q34622578-258C4CB3-7658-4971-B904-65F2B8121CD1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
ricercatore
@it
հետազոտող
@hy
name
Ronald van Vollenhoven
@ast
Ronald van Vollenhoven
@br
Ronald van Vollenhoven
@ca
Ronald van Vollenhoven
@cs
Ronald van Vollenhoven
@cy
Ronald van Vollenhoven
@da
Ronald van Vollenhoven
@de
Ronald van Vollenhoven
@de-at
Ronald van Vollenhoven
@de-ch
Ronald van Vollenhoven
@en
type
label
Ronald van Vollenhoven
@ast
Ronald van Vollenhoven
@br
Ronald van Vollenhoven
@ca
Ronald van Vollenhoven
@cs
Ronald van Vollenhoven
@cy
Ronald van Vollenhoven
@da
Ronald van Vollenhoven
@de
Ronald van Vollenhoven
@de-at
Ronald van Vollenhoven
@de-ch
Ronald van Vollenhoven
@en
altLabel
R. van Vollenhoven
@nl
Ronald F van Vollenhoven
@en
Ronald F. van Vollenhoven
@en
prefLabel
Ronald van Vollenhoven
@ast
Ronald van Vollenhoven
@br
Ronald van Vollenhoven
@ca
Ronald van Vollenhoven
@cs
Ronald van Vollenhoven
@cy
Ronald van Vollenhoven
@da
Ronald van Vollenhoven
@de
Ronald van Vollenhoven
@de-at
Ronald van Vollenhoven
@de-ch
Ronald van Vollenhoven
@en
P2671
P106
P1153
7004564883
P21
P214
171145542441096640496
P2671
/g/11b7qc52sx
P31
P496
0000-0001-6438-8663
P569
1960-01-01T00:00:00Z
P734
P735
P7449
PRS1334432
P7859
viaf-171145542441096640496